{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:48:31Z","timestamp":1785775711169,"version":"3.56.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T00:00:00Z","timestamp":1579219200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T00:00:00Z","timestamp":1579219200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1038\/s41409-020-0786-8","type":"journal-article","created":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T14:03:01Z","timestamp":1579269781000},"page":"1085-1092","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A prospective evaluation on the interaction of fluconazole and voriconazole on serum concentrations of budesonide in patients treated for gastrointestinal GVHD"],"prefix":"10.1038","volume":"55","author":[{"given":"Thomas E.","family":"Hughes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Stansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parag","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tat\u2019Yana","family":"Worthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W.","family":"Childs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,17]]},"reference":[{"key":"786_CR1","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.bbmt.2008.12.487","volume":"15","author":"RB Ibrahim","year":"2009","unstructured":"Ibrahim RB, Abidi MH, Cronin SM, Lum LG, Al-Kadhimi Z, Ratanatharathorn V, et al. Nonabsorbable corticosteroids use in the treatment of gastrointestinal graft-versus-host disease. Biol Blood Marrow Transpl. 2009;15:395\u2013405.","journal-title":"Biol Blood Marrow Transpl"},{"key":"786_CR2","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1097\/00007890-199512000-00010","volume":"60","author":"PH Baeher","year":"1995","unstructured":"Baeher PH, Levine DS, Bouvier ME, Hockenbery DM, Gooley TA, Stern JG, et al. Oral beclomethasone dipropionate for treatment of human intestinal graft-versus-host disease. Transplantation. 1995;60:1231\u20138.","journal-title":"Transplantation"},{"key":"786_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/S0016-5085(98)70361-0","volume":"115","author":"GB McDonald","year":"1998","unstructured":"McDonald GB, Bouvier M, Hockenbery DM, Stern JM, Gooley T, Farrand A, et al. Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a randomized, controlled trial. Gastroenterology. 1998;115:28\u201335.","journal-title":"Gastroenterology"},{"key":"786_CR4","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.bbmt.2005.04.008","volume":"11","author":"RV Iyer","year":"2005","unstructured":"Iyer RV, Hahn T, Roy HN, Battiwalla M, Cooper M, Anderson B, et al. Long-term use of oral beclomethasone dipropionate for the treatment of gastrointestinal graft-versus-host disease. Biol Blood Marrow Transpl. 2005;11:587\u201392.","journal-title":"Biol Blood Marrow Transpl"},{"key":"786_CR5","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.bbmt.2006.05.010","volume":"12","author":"C Castilla","year":"2006","unstructured":"Castilla C, Perez-Simon A, Sanchez-Guijo M, Diez-Campelo M, Ocio E, Perez-Persona O, et al. Oral beclomethasone dipropionate for the treatment of gastrointestinal acute graft-versus-host disease (GVHD). Biol Blood Marrow Transpl. 2006;12:936\u201341.","journal-title":"Biol Blood Marrow Transpl"},{"key":"786_CR6","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/sj.bmt.1705489","volume":"38","author":"Y Miura","year":"2006","unstructured":"Miura Y, Narimatsu H, Kami M, Kusumi E, Matsumura T, Yuji K, et al. Oral beclomethasone dipropionate as an initial treatment of gastrointestinal acute graft-versus-host disease after reduced-intensity cord blood transplantation (letter). Bone Marrow Transpl. 2006;38:577\u20139.","journal-title":"Bone Marrow Transpl"},{"key":"786_CR7","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1182\/blood-2006-05-021139","volume":"109","author":"DM Hockenbery","year":"2007","unstructured":"Hockenbery DM, Cruickshank S, Rodell TC, Gooley T, Schuening FG, Rowley SD, et al. A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood. 2007;109:4557\u201363.","journal-title":"Blood"},{"key":"786_CR8","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/j.bbmt.2009.05.018","volume":"15","author":"FN Villanueva","year":"2009","unstructured":"Villanueva FN, Perez-Simon JA, Silva FF, Caballero-Velazquez TT, Sanchez-Guijo FF, Canizo CC, et al. Oral beclomethasone dipropionate for the treatment of gastrointestinal chronic graft-versus-host disease. Biol Blood Marrow Transpl. 2009;15:1331\u20136.","journal-title":"Biol Blood Marrow Transpl"},{"key":"786_CR9","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/bmt.2008.209","volume":"42","author":"H Andree","year":"2008","unstructured":"Andree H, Hilgendorf I, Leithaueuser M, Junghanss C, Holzhueter S, Loddenkemper C, et al. Enteral budesonide in treatment for mild and moderate gastrointestinal chronic GVHD. Bone Marrow Transpl. 2008;42:541\u20136.","journal-title":"Bone Marrow Transpl"},{"key":"786_CR10","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/sj.bmt.1702055","volume":"24","author":"H Bertz","year":"1999","unstructured":"Bertz H, Afting M, Kreisel W, Duffner U, Greinwald R, Finke J. Feasibility and response to budesonide as topical corticosteroid therapy for acute intestinal GVHD. Bone Marrow Transpl. 1999;24:1185\u20139.","journal-title":"Bone Marrow Transpl"},{"key":"786_CR11","first-page":"137","volume":"23","author":"G Jonsson","year":"1994","unstructured":"Jonsson G, Astrom A, Andersson P. Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metab Dispos. 1994;23:137\u201342.","journal-title":"Drug Metab Dispos"},{"key":"786_CR12","unstructured":"Product information. Entocort EC (budesonide). Wilmington, DE: AstraZeneca; 2011."},{"key":"786_CR13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/sj.clpt.6100505","volume":"84","author":"M Ufer","year":"2008","unstructured":"Ufer M, Dilger K, Leschhorn L, Daufresne LM, Mosyagin I, Rosenstiel P, et al. Influence of CYP3A4, CYP3A5, and ABCB1 genotype and expression on budesonide pharmacokinetics: a possible role of intestinal CYP3A4 expression. Clin Pharmacol Ther. 2008;84:43\u20136.","journal-title":"Clin Pharmacol Ther"},{"key":"786_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1067\/mcp.2000.106895","volume":"68","author":"J Seidegard","year":"2000","unstructured":"Seidegard J. Reduction of the inhibitory effect of ketoconazole on budesonide pharmacokinetics by separation of their time of administration. Clin Pharmacol Ther. 2000;68:13\u201317.","journal-title":"Clin Pharmacol Ther"},{"key":"786_CR15","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/bmt.2012.17","volume":"47","author":"R El Fakih","year":"2012","unstructured":"El Fakih R, Obi GA, Scholoff A, Carrum G, Kamble RT. Systemic effects of oral budesonide in hematopoietic transplant: implications of drug interaction with azoles (letter). Bone Marrow Transpl. 2012;47:1370\u20131.","journal-title":"Bone Marrow Transpl"},{"key":"786_CR16","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.1002\/phar.1432.","volume":"34","author":"W Jones","year":"2014","unstructured":"Jones W, Chastain CA, Wright PW. Iatrogenic Cushing syndrome secondary to a probable interaction between voriconazole and budesonide. Pharmacotherapy. 2014;34:e116\u20139. https:\/\/doi.org\/10.1002\/phar.1432.","journal-title":"Pharmacotherapy"},{"key":"786_CR17","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1345\/aph.1P731","volume":"45","author":"JK Frankel","year":"2011","unstructured":"Frankel JK, Packer CD. Cushing\u2019s syndrome due to antiretroviral-budesonide interaction (letter). Ann Pharmacother. 2011;45:823\u20134.","journal-title":"Ann Pharmacother"},{"key":"786_CR18","doi-asserted-by":"publisher","first-page":"296","DOI":"10.7196\/SAMJ.3848","volume":"100","author":"D Gray","year":"2010","unstructured":"Gray D, Roux P, Carrihill M, Klein M. Adrenal suppression and Cushing\u2019s syndrome secondary to ritonavir and budesonide (letter). S Afr Med J. 2010;100:296\u20137.","journal-title":"S Afr Med J"},{"key":"786_CR19","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3109\/02770903.2010.485666","volume":"47","author":"E Kedem","year":"2010","unstructured":"Kedem E, Shahar E, Hassoun G, Pollack S. Iatrogenic Cushing\u2019s syndrome due to coadministration of ritonavir and inhaled budesonide in an asthmatic human immunodeficiency virus infected patient. J Asthma. 2010;47:830\u20131.","journal-title":"J Asthma"},{"key":"786_CR20","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1258\/ijsa.2011.011408","volume":"23","author":"K Yoganathan","year":"2012","unstructured":"Yoganathan K, David L, Williams C, Jones K. Cushing\u2019s syndrome with adrenal suppression induced by inhaled budesonide due to a ritonavir drug interaction in a woman with HIV infection. Int J STD AIDS. 2012;23:520\u20131.","journal-title":"Int J STD AIDS"},{"key":"786_CR21","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1177\/2325957417736612","volume":"16","author":"L Colpitts","year":"2017","unstructured":"Colpitts L, Murray TB, Tahhan SG, Boggs JP. Iatrogenic Cushing syndrome in a 47-year-old HIV-positive woman on ritonavir and inhaled budesonide. J Int Assoc Provid AIDS Care. 2017;16:531\u20134.","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"786_CR22","doi-asserted-by":"publisher","first-page":"E1188","DOI":"10.1503\/cmaj.170415.","volume":"189","author":"O Veilleux","year":"2017","unstructured":"Veilleux O, Lee TC, McDonald EG. Rebound adrenal insufficiency after withdrawal of ritonavir in a 65-year-old man using inhaled budesonide. CMAJ. 2017;189:E1188\u201391. https:\/\/doi.org\/10.1503\/cmaj.170415.","journal-title":"CMAJ"},{"key":"786_CR23","doi-asserted-by":"publisher","first-page":"e138","DOI":"10.4158\/EP13122.CR","volume":"19","author":"MC Blondin","year":"2013","unstructured":"Blondin MC, Beauregard H, Serri O. Iatrogenic Cushing syndrome in patients receiving inhaled budesonide and itraconazole or ritonavir: two cases and literature review. Endocr Pract. 2013;19:e138\u201341.","journal-title":"Endocr Pract"},{"key":"786_CR24","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/S1569-1993(03)00022-5","volume":"2","author":"E De Wachter","year":"2003","unstructured":"De Wachter E, Malfroot A, De Schutter I, Vanbesien J, De Schepper J. Inhaled budesonide induced Cushing\u2019s syndrome in cystic fibrosis patients, due to drug inhibition of cytochrome P450. J Cyst Fibros. 2003;2:72\u20135.","journal-title":"J Cyst Fibros"},{"key":"786_CR25","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1345\/aph.1D222","volume":"38","author":"MJ Bolland","year":"2004","unstructured":"Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN. Cushing\u2019s Syndrome due to interaction between inhaled corticosteroids and itraconazole. Ann Pharmacother. 2004;38:46\u20139.","journal-title":"Ann Pharmacother"},{"key":"786_CR26","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/jac\/dkt508","volume":"69","author":"HR Ashbee","year":"2014","unstructured":"Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrobial Chemother. 2014;69:1162\u201376.","journal-title":"J Antimicrobial Chemother"},{"key":"786_CR27","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1111\/imj.12600","volume":"44","author":"MM Chau","year":"2014","unstructured":"Chau MM, Kong DCM, van Hal SJ, Urbancic K, Trubiano JA, Cassumbhoy M, et al. Consensus guidelines for optimizing antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014. Intern Med J. 2014;44:1364\u201388.","journal-title":"Intern Med J"},{"key":"786_CR28","doi-asserted-by":"publisher","first-page":"334","DOI":"10.7326\/0003-4819-101-3-334","volume":"101","author":"BS Graham","year":"1984","unstructured":"Graham BS, Tucker WS. Opportunistic infections in endogenous Cushing\u2019s syndrome. Ann Int Med. 1984;101:334\u20138.","journal-title":"Ann Int Med"},{"key":"786_CR29","first-page":"42","volume":"85","author":"NJ Sarlis","year":"2000","unstructured":"Sarlis NJ, Chanock SJ, Nieman LK. Cortisolemic indices predict severe infections in Cushing syndrome due to ectopic production of adrenocorticotropin. J Clin Endocrinol Metab. 2000;85:42\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"786_CR30","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/0091-6749(89)90297-2","volume":"84","author":"JH Toogood","year":"1989","unstructured":"Toogood JH, Baskerville J, Jennings B, Lefcoe NM, Johansson SA. Bioequivalent doses of budesonide and prednisone in moderate and severe asthma. J Allergy Clin Immunol. 1989;84:688\u2013700.","journal-title":"J Allergy Clin Immunol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-0786-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-0786-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-0786-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:17:34Z","timestamp":1684617454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-0786-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,17]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["786"],"URL":"https:\/\/doi.org\/10.1038\/s41409-020-0786-8","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,17]]},"assertion":[{"value":"1 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}